← All trials
NCT00271596
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2005
- Primary completion
- Apr 1, 2011
- Completion date
- Nov 1, 2011
- First posted
- —
- Last posted
- —
- Enrollment
- 33
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of IowaLead sponsor
- University of RochesterOverall official - principal investigator
- Mayo ClinicOverall official - principal investigator
- University of IowaOverall official - principal investigator
- National Institute of Neurological Disorders and Stroke (NINDS)Collaborator
- University of RochesterCollaborator
- Mayo ClinicCollaborator
- Cure Huntington's Disease InitiativeCollaborator
- University of IowaReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.